Market Closed -
Nasdaq
04:00:00 2024-07-05 pm EDT
|
5-day change
|
1st Jan Change
|
0.8
USD
|
-2.44%
|
|
-20.00%
|
-48.72%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
309
|
633.5
|
198.8
|
110.1
|
-
|
-
|
Enterprise Value (EV)
1 |
309
|
633.5
|
198.8
|
110.1
|
110.1
|
110.1
|
P/E ratio
|
-2.42
x
|
-13.6
x
|
-4.73
x
|
-2.07
x
|
-1.84
x
|
-3.08
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
20.7
x
|
1.59
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
20.7
x
|
1.59
x
|
EV / EBITDA
|
-3.8
x
|
-15.5
x
|
-4
x
|
-1.89
x
|
-1.73
x
|
-1.78
x
|
EV / FCF
|
-14,336,714
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
97,472
|
125,938
|
127,455
|
137,589
|
-
|
-
|
Reference price
2 |
3.170
|
5.030
|
1.560
|
0.8000
|
0.8000
|
0.8000
|
Announcement Date
|
3/18/22
|
3/15/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
5.329
|
69.08
|
EBITDA
1 |
-
|
-81.32
|
-40.87
|
-49.66
|
-58.16
|
-63.62
|
-61.96
|
EBIT
1 |
-
|
-81.88
|
-41.66
|
-50.36
|
-57.15
|
-68.59
|
-38.35
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-1,287.21%
|
-55.52%
|
Earnings before Tax (EBT)
1 |
-29.47
|
-82.18
|
-39.22
|
-42.49
|
-52.63
|
-66.05
|
-35.04
|
Net income
1 |
-29.5
|
-82.18
|
-39.22
|
-42.49
|
-54.51
|
-71.37
|
-45.25
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-1,339.45%
|
-65.5%
|
EPS
2 |
-
|
-1.310
|
-0.3700
|
-0.3300
|
-0.3871
|
-0.4357
|
-0.2600
|
Free Cash Flow
|
-
|
-21.55
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/21
|
3/18/22
|
3/15/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-12.88
|
-7.017
|
-8.767
|
-12.4
|
-12.69
|
-9.517
|
-13.16
|
-11.76
|
-15.23
|
-12.62
|
-13.98
|
-15.06
|
-16.4
|
-14.67
|
-14.95
|
EBIT
1 |
-13
|
-7.182
|
-8.987
|
-12.6
|
-12.89
|
-9.711
|
-13.34
|
-11.93
|
-15.39
|
-12.77
|
-13.74
|
-13.98
|
-15.29
|
-14.82
|
-15.11
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.99
|
-7.162
|
-8.494
|
-11.98
|
-11.59
|
-7.837
|
-11.28
|
-9.964
|
-13.42
|
-10.79
|
-12.83
|
-13.4
|
-15.02
|
-14.82
|
-15.11
|
Net income
1 |
-12.98
|
-7.162
|
-8.494
|
-11.98
|
-11.59
|
-7.837
|
-11.28
|
-9.964
|
-13.42
|
-10.79
|
-13.21
|
-14.1
|
-15.9
|
-14.82
|
-15.11
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0500
|
-0.0700
|
-0.0800
|
-0.1200
|
-0.1000
|
-0.0600
|
-0.0900
|
-0.0800
|
-0.1100
|
-0.0800
|
-0.0957
|
-0.1000
|
-0.1086
|
-0.0900
|
-0.0900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/22
|
5/9/22
|
8/1/22
|
11/9/22
|
3/15/23
|
5/4/23
|
8/3/23
|
11/9/23
|
3/21/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-21.6
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.89
|
0.21
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/21
|
3/18/22
|
3/15/23
|
3/21/24
|
-
|
-
|
-
|
Average target price
8.833
USD Spread / Average Target +1,004.17% Consensus |
1st Jan change
|
Capi.
|
---|
| -48.72% | 110M | | +16.61% | 122B | | +17.75% | 112B | | +17.23% | 25.91B | | -24.11% | 19.33B | | -18.56% | 16.17B | | -18.47% | 15.6B | | -47.75% | 14.65B | | +57.35% | 14.34B | | +5.62% | 14B |
Bio Therapeutic Drugs
|